ION expands ETF trading capabilities with Tradeweb integration
DUBLIN - Morgan Stanley & Co. International plc disclosed Thursday that it purchased and subsequently sold 33,364 ordinary shares of Avadel Pharmaceuticals plc on October 22, 2025, according to a regulatory filing with the Irish Takeover Panel.
The transactions were executed at prices ranging from $18.5106 to $18.5650 per share, as reported in the dealing disclosure made under Rule 38.5(a) of the Irish Takeover Panel Act.
Morgan Stanley is acting as a connected exempt principal trader with recognized intermediary status in a client-serving capacity related to Avadel Pharmaceuticals. The disclosure indicates that the firm purchased and sold an identical number of shares on the same day.
The filing was submitted in compliance with Irish takeover regulations, which require disclosure of dealings by connected parties during offer periods. No indemnity arrangements or agreements relating to options or derivatives were reported in connection with these transactions.
The information was provided through a Regulatory Information Service as required by Rule 38 of the Irish Takeover Rules, based on a press release statement issued by Morgan Stanley.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.